|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest U.S. meeting of anterior segment surgeons, which integrates a scientific program dedicated to the needs of surgeons, specialists, practice management staff, and ophthalmic technicians and nurses.
SAN DIEGO, March 12, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights:.
Harrow Health, Inc. (HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L. Baum, the company’s Chief Executive Officer, and Andrew R. Boll, its Chief Financial Officer, will be hosting one-on-one meetings at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. Harrow Health, Inc. (HROW) owns a portfolio of healthcare businesses, including the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.
Harrow Health, Inc. (HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 369-8770 for domestic callers or (862) 298-0840 for international callers. To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here. A dial in replay of the call will be available until April 12, 2019. To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 44882. The webcast replay will be available until June 12, 2019.
Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,166,240 and 10,179,136 relate to methods of use, formulation compositions and methods to manufacture the same, which the company intends to commercialize through its MELT-100 program and other planned drug development initiatives. Both new patents have expiration dates in 2036. Melt Pharmaceuticals, Inc., is a development stage specialty pharmaceutical company focused on the development and commercialization of patented non-opioid and non-intravenous (or non-IV) sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Melt intends to seek regulatory approval through the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway for these proprietary technologies. Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.
SAN DIEGO, Feb. 07, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and.
Concurrent with the financing, Greg Madison has been hired as CEO of Melt Pharmaceuticals. Most recently, Mr. Madison was CEO of Keryx Biopharmaceuticals where he led the company’s transformation from development stage to a fully integrated 200+ employee commercial organization and drove impressive revenue growth by expanding the label for the company’s lead product. Before Keryx, he was Chief Commercial Officer at specialty pharma company AMAG Pharmaceuticals and spent 12 years at Genzyme/Sanofi, ending as Vice-President and General Manager of the Renal division.
Mark L. Baum, CEO of Harrow Health, stated, “Our new name reflects our business model of creating, investing in, operating and growing a diversified portfolio of healthcare businesses that meet the needs of healthcare providers and patients across America. Harrow Health’s businesses and subsidiaries each have strong brand equity and will continue to operate under the Harrow Health corporate umbrella using their existing names. This includes Harrow Health’s wholly-owned subsidiaries ImprimisRx, the nation’s leading ophthalmology pharmaceutical compounding business, and Park Compounding.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.